Abstract
No public abstract is available from the verified source records.
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureChenming Liu, Jingli Liu, Peirong Tian, Mengyi Li, Zhongtao Zhang
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Obesity: global epidemiology and pathogenesis
10.1038/s41574-019-0176-8 · 2019
Mechanisms, pathophysiology, and management of obesity
10.1056/nejmra1514009 · 2017
2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery
10.1016/j.soard.2022.08.013 · 2022
Once-weekly semaglutide in adults with overweight or obesity
10.1056/nejmoa2032183 · 2021
Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial
10.1001/jama.2021.3224 · 2021
Pharmacology, physiology, and mechanisms of incretin hormone action
10.1016/j.cmet.2013.04.008 · 2013
The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: a pathophysiological update
10.1111/dom.14496 · 2021
Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans
10.2337/db10-0474 · 2011
The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity
10.1111/dom.14280 · 2021
Glucose-dependent insulinotropic polypeptide (GIP)
10.1016/j.molmet.2025.102118 · 2025
Tirzepatide once weekly for the treatment of obesity
10.1056/nejmoa2206038 · 2022
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes
10.1056/nejmoa2107519 · 2021
Investigating GIPR (ant)agonism: a structural analysis of GIP and its receptor
10.1016/j.str.2021.04.001 · 2021
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
10.1016/j.molmet.2018.12.001 · 2019
Stimulating intestinal GIP release reduces food intake and body weight in mice
10.1016/j.molmet.2024.101945 · 2024
Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in mice
10.1038/s42255-023-00931-7 · 2023
Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies
10.1016/j.molmet.2025.102298 · 2026
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
10.1038/nm727 · 2002
Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure
10.1172/jci25483 · 2007
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
10.1126/scitranslmed.aat3392 · 2018
Glucose-Dependent Insulinotropic Polypeptide Receptor Therapies for the Treatment of Obesity, Do Agonists = Antagonists
10.1210/endrev/bnz002 · 2020
Therapeutic Targeting of the GIP Receptor-Revisiting the Controversies
10.2337/db25-0393 · 2025
GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale
10.2337/dbi24-0027 · 2025
The Premise of the Paradox: Examining the Evidence That Motivated GIPR Agonist and Antagonist Drug Development Programs
10.3390/jcm14113812 · 2025
GIP(6-30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42 action in vitro
10.1016/s0167-0115(97)00009-8 · 1997
Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats
10.2337/diabetes.51.3.652 · 2002
NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity
10.2337/diabetes.48.4.758 · 1999
Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide
10.1677/joe.0.1650639 · 2000
Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin
10.1007/s00125-002-1028-x · 2003
Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes
10.2337/diabetes.54.8.2436 · 2005
Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets
10.1007/s00125-007-0710-4 · 2007
A gastric inhibitory polypeptide. II. The complete amino acid sequence
10.1139/o71-122 · 1971
Stimulation of insulin secretion by gastric inhibitory polypeptide in man
10.1210/jcem-37-5-826 · 1973
Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans
10.2337/db11-0979 · 2011
Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor
10.2337/diab.44.10.1202 · 1995
Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain
10.1210/endo.133.6.8243312 · 1993
Characterization of genetic variants of GIPR reveals a contribution of β-arrestin to metabolic phenotypes
10.1038/s42255-024-01061-4 · 2024
The Role of Incretins on Insulin Function and Glucose Homeostasis
10.1210/endocr/bqab065 · 2021
The early history of GIP 1969-2000: From enterogastrone to major metabolic hormone
10.1016/j.peptides.2020.170276 · 2020
GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells
10.1126/sciadv.abf1948 · 2021
10.1002/oby.22719
10.1002/oby.22719 · doi-reference
The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery-a retrospective analysis
10.1007/s11695-022-06211-9 · doi-reference
Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study
10.1007/s11695-023-06484-8 · doi-reference
Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence
10.1002/oby.23736 · doi-reference
Sleeve-to-bypass conversion vs. sleeve-with-adjuvant GLP-1 receptor agonists: an academic multicenter retrospective study
10.1007/s00464-025-11942-8 · doi-reference
Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Suboptimal Initial Clinical Response and Weight Gain Recurrence After Bariatric Surgery: a Systematic Review and Meta-analysis
10.1007/s11695-025-07733-8 · doi-reference
Effects of Semaglutide and Tirzepatide on Recurrent Weight Gain After Bariatric Surgery: A Systematic Review and Meta-analysis
10.1007/s11695-025-08414-2 · doi-reference
GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis
10.1007/s00423-025-03831-4 · doi-reference
Semaglutide and Tirzepatide for the Management of Weight Recurrence After Sleeve Gastrectomy: A Retrospective Cohort Study
10.1007/s11695-024-07137-0 · doi-reference
Weight Regain Following Sleeve Gastrectomy-a Systematic Review
10.1007/s11695-016-2152-x · doi-reference
Mechanisms of weight recurrence after bariatric surgery
10.1186/s12986-026-01115-2 · doi-reference
Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery
10.1038/ijo.2016.121 · doi-reference
The Importance of Endogenously Secreted GLP-1 and GIP for Postprandial Glucose Tolerance and β-Cell Function After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy Surgery
10.2337/db22-0568 · doi-reference
Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in subjects with Type 2 diabetes and normal glucose tolerance
10.1152/ajpendo.00073.2012 · doi-reference
A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice
10.1111/dom.70300 · doi-reference
Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation
10.1016/j.molmet.2025.102094 · doi-reference
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
10.1038/s41467-020-18751-8 · doi-reference
Specific loss of GIPR signaling in GABAergic neurons enhances GLP-1R agonist-induced body weight loss
10.1016/j.molmet.2024.102074 · doi-reference
Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism
10.1038/s42255-026-01575-z · doi-reference
GIPR-Ab/GLP-1 peptide-antibody conjugate requires brain GIPR and GLP-1R for additive weight loss in obese mice
10.1038/s42255-025-01295-w · doi-reference
GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice
10.1038/s42255-025-01294-x · doi-reference
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial
10.1056/nejmoa2504214 · doi-reference
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings
10.1038/s42255-023-00966-w · doi-reference
AT-7687, a novel GIPR peptide antagonist, combined with a GLP-1 agonist, leads to enhanced weight loss and metabolic improvements in cynomolgus monkeys
10.1016/j.molmet.2024.102006 · doi-reference
Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism
10.1371/journal.pone.0249239 · doi-reference
Pharmacological antagonism of the incretin system protects against diet-induced obesity
10.1016/j.molmet.2019.11.018 · doi-reference
Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice
10.1002/osp4.164 · doi-reference
Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3-30)NH(2) on GIP actions in humans
10.1111/dom.14186 · doi-reference
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture
10.1038/ng.2606 · doi-reference
Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge
10.1038/ng.521 · doi-reference
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
10.1038/ng.686 · doi-reference
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
10.1056/nejmoa2301972 · doi-reference
GIPR Agonism Inhibits PYY-Induced Nausea-Like Behavior
10.2337/db21-0848 · doi-reference
GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models
10.2337/db21-0459 · doi-reference
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
10.1001/jama.2023.24945 · doi-reference
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
10.1038/s41591-023-02597-w · doi-reference
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
10.1172/jci.insight.140532 · doi-reference
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
10.1016/s0140-6736(18)32260-8 · doi-reference
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
10.1016/j.molmet.2018.09.009 · doi-reference
Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans
10.1126/scitranslmed.3007218 · doi-reference